# Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia

> **NCT03513484** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Northwestern University** · enrollment: 44 (estimated)

## Conditions studied

- Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A
- Fibroblast Growth Factor Basic Form Measurement
- FLT3 Internal Tandem Duplication
- Recurrent Adult Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia

## Interventions

- **DRUG:** Azacitidine
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Nintedanib

## Key facts

- **NCT ID:** NCT03513484
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-11-14
- **Primary completion:** 2023-12-11
- **Final completion:** 2027-01
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2025-10-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03513484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03513484, "Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03513484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*